Mutations in HBV reverse transcriptase region in patients with chronic hepatitis B after nucleot(s)ide analogues withdrawal
LI Quanshuang1,2 DENG Yanchao1,2▲ CHENG Xing2 PEI Yunfeng2 ZHOU Jing2 SHEN Hongyan1,2 XU Zhan1,2
1.Xuzhou Institute of Medical Sciences, Jiangsu Province, Xuzhou 221006, China;
2.The Affiliated Xuzhou Central Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, Xuzhou 221006, China
Abstract:Objective To investigate the mutation of hepatitis B viurs DNA reverse transcriptase in chronic hepatitis B patients with relapse after nucleot(s)ide analogues withdrawal. Methods From January 2014 to January 2016, in Xuzhou Central Hospital, 110 serum samples of patients with chronic hepatitis B were collected. Patients took nucleoside (acid) drugs for more than 6 months; due to various reasons, patients after withdrawal of the disease recurrence. HBV resistance mutation sites and genotypes were detected by PCR- reverse dot blot hybridization. Results There were 62 drug resistant mutations, the detection rate was 56.36%; including 36 cases of rtL180M (32.73%), 24 cases of rtM204I (21.82%), 24 cases of rtM204V (21.82%), 14 cases of rtA181V (12.73%); the number of patients with drug resistance was 58 cases (52.73%), and the main patterns of mutation were L180M+M204I/V, M204I, A181V. Drug resistance rates of Lamivudine (LMV), telbivudine (LDT), adefovir dipivoxil (ADV) was 52.73%, 22.73%, 14.55% respectively; there were 43 patients with entecavir resistance risk (39.09%) among them. 24 patients were resistant to LMV and LDT, the ratio was 21.82%; 14 patients were resistant to LMV and ADV, the ratio was 12.73%; 2 patients were resistant to LMV, LDT, ADV, the ratio was 1.82%. Mutations in the HBV RT region were independent of age, sex, genotype (P > 0.05). Conclusion The incidence of drug resistance mutation in chronic hepatitis B patients with relapse after withdrawal was higher; it is necessary to detect the mutations in chronic hepatitis B patients with relapse after withdrawal, so as to provide basis for clinical treatment.